Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Polycythemia Market CAGR Outlook And Future Development
The polycythemia market has demonstrated significant growth in recent years. It is anticipated to expand from $4.68 billion in 2025 to $4.99 billion in 2026, with a compound annual growth rate (CAGR) of 6.7%. Historically, this growth can be ascribed to factors such as the increasing prevalence of myeloproliferative disorders, heightened awareness of rare blood diseases, the proliferation of specialty hematology centers, higher rates of diagnostic testing, and the increased use of cytoreductive drugs.
The polycythemia market is anticipated to experience substantial growth in the upcoming years. It is projected to reach $6.53 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This expansion throughout the forecast period is propelled by advancements in targeted JAK2 treatments, a rise in genetic screening adoption, increasing needs for individualized treatment strategies, broadening availability of specialty biologics, and the expanding demographic of older adults. Key developments expected during this period involve the increasing embrace of Janus kinase inhibitors, a surge in the application of interferon-based injectable treatments, a growing inclination towards therapeutic phlebotomy, the enlargement of hematocrit monitoring diagnostic capabilities, and a movement towards combination drug therapy methodologies.
Get A Free Sample Report With In-Depth Market Insights:
Polycythemia Market Expansion Drivers: What’s Shaping Future Growth?
The increasing occurrence of myeloproliferative diseases is anticipated to boost the expansion of the polycythemia market in the future. These rare blood conditions are characterized by the abnormal overproduction of blood cells within the bone marrow, leading to compromised blood function and circulation. A significant contributor to the rise in these disorders is the growing prevalence of age-related hematological abnormalities, as older populations are more susceptible to bone marrow dysfunction. Polycythemia, being a primary subtype of myeloproliferative diseases involving excessive red blood cell production, plays a crucial role in improving clinical recognition, diagnosis, and continuous oversight of these conditions, thereby fostering market growth. For instance, in September 2024, Blood Cancer United, a US-based nonprofit dedicated to curing blood cancers, estimated that over 120,000 people in the United States were living with or in remission from myeloproliferative neoplasms (MPNs) in 2023, indicating an increased prevalence of these chronic hematologic disorders. Consequently, the rising incidence of myeloproliferative diseases is fueling the growth of the polycythemia market.
Polycythemia Market Segmentation: How Does The Market Break Down By Category?
The polycythemia market covered in this report is segmented –
1) By Type: Primary polycythemia; Secondary polycythemia; Pseudopolycythemia
2) By Drug Class: Antimetabolites; Janus Kinase 2 Inhibitors; Myelosuppressive Agents; Selective Serotonin Reuptake Inhibitors; Folic Acid; Other Drug Classes
3) By Route Of Administration: Oral; Intravenous; Intramuscular
4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Primary Polycythemia: Polycythemia Vera; Familial Primary Polycythemia
2) By Secondary Polycythemia: Hypoxia Induced Polycythemia; Tumor Associated Polycythemia; Drug Induced Polycythemia; Hormone Induced Polycythemia
3) By Pseudopolycythemia: Stress Related Polycythemia; Dehydration Related Polycythemia; Plasma Volume Contraction Related Polycythemia
Polycythemia Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies operating in the polycythemia market are prioritizing advanced innovations such as rusfertide, a first-in-class hepcidin mimetic peptide, which significantly reduces the necessity for frequent phlebotomies while also enhancing hematocrit control and the patient’s quality of life. A hepcidin mimetic is characterized as a drug or compound specifically designed to function like hepcidin, the body’s primary hormone responsible for regulating iron balance. As an illustration, in March 2025, Takeda Pharmaceutical Company Limited, a biopharmaceutical company based in Japan, announced favorable topline results from its Phase 3 VERIFY study of rusfertide in patients with polycythemia vera. These findings demonstrated a notable reduction in phlebotomy dependence, improved hematocrit control, and meaningful patient-reported outcomes, all while maintaining an advantageous safety profile.
Polycythemia Market Key Players Shaping Industry Direction
Major companies operating in the polycythemia market are Bristol Myers Squibb Company, Roche Holding AG, Merck And Company Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, Ionis Pharmaceuticals Inc., CTI BioPharma Corp., AOP Orphan Pharmaceuticals AG, Silence Therapeutics Plc, Italfarmaco S.p.A., PharmaEssentia Corporation, Karyopharm Therapeutics Inc., Protagonist Therapeutics Inc., Kartos Therapeutics Inc., Geron Corporation, and Perseus Proteomics Inc.
View The Full Polycythemia Market Report:
Polycythemia Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the polycythemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polycythemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
